financetom
VRTX
financetom
/
Healthcare
/
VRTX
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Vertex Pharmaceuticals IncorporatedVRTX
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).

It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations.

The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial.

In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial.

Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics.

Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Latest News >
Sector Update: Health Care
Sector Update: Health Care
Jan 7, 2025
03:34 PM EST, 01/07/2025 (MT Newswires) -- Health care stocks rose late Tuesday afternoon with the NYSE Health Care Index adding 0.7% and the Health Care Select Sector SPDR Fund (XLV) up 0.3%. The iShares Biotechnology ETF (IBB) advanced 0.7%. In corporate news, Citius Pharmaceuticals ( CTXR ) shares were up nearly 7% after the company and its Citius Oncology...
Willdan Group Secures $11 Million Energy Modernization Project in South Lake Tahoe
Willdan Group Secures $11 Million Energy Modernization Project in South Lake Tahoe
Jan 7, 2025
03:32 PM EST, 01/07/2025 (MT Newswires) -- Willdan Group ( WLDN ) Tuesday afternoon said it has received an $11 million contract to modernize energy infrastructure for the city of South Lake Tahoe, California. The project will improve operational efficiencies and reduce carbon emissions and includes the installation of a cogeneration microturbine, photovoltaic solar panels, and advanced automation systems for...
Update: Aurora Innovation Partners With Continental, Nvidia to Deploy Driverless Trucks at Scale
Update: Aurora Innovation Partners With Continental, Nvidia to Deploy Driverless Trucks at Scale
Jan 7, 2025
03:31 PM EST, 01/07/2025 (MT Newswires) -- (Updates with recent share price movement in the first paragraph.) Aurora Innovation ( AUR ) shares were up 30% Tuesday afternoon after the autonomous driving technology company said it formed a long-term strategic partnership with Continental and Nvidia ( NVDA ) to deploy driverless trucks at scale using Nvidia's ( NVDA ) Drive...
Shell Shares Are On The Rise Today: What's going On?
Shell Shares Are On The Rise Today: What's going On?
Jan 7, 2025
Shell PLC ( SHEL ) shares are trading higher Tuesday following an upgrade from Morgan Stanley. Martijn Rats upgraded Shell shares from Equal-Weight to Overweight and raised the price target from $66.50 to $79.80, reflecting a 20% potential upside. Rats concluded that Shell's financial strength, combined with a favorable valuation, makes it well-positioned to weather ongoing challenges in the energy...
Copyright 2023-2025 - www.financetom.com All Rights Reserved